CIPN

AcronymDefinition
CIPNChemotherapy-Induced Peripheral Neuropathy
CIPNChemotherapy-Induced Peripheral Neurotoxicity
CIPNCisplatin-Induced Peripheral Neuropathy
CIPNCalifornia Injury Prevention Network
CIPNCentre for Intellectual Property Nepal (Nepal)
References in periodicals archive ?
Cisplatin, a platinum-based chemotherapeutic agent, as well as taxanes, are commonly used for the treatment of solid tumors but are associated with a high incidence of CIPN.
NEMUS CEO and CMO, Brian Murphy, said, 'The CIPN market comprises roughly 1.
The side effects include CIPN, pain, sleeplessness, nausea and depression.
The data suggest that acupuncture has a positive effect on CIPN, as measured by objective parameters [nerve conduction studies]," said authors.
Address : EDF SA Direction Des Achats Agence Achat Ingnierie CIPN
Oncology nurses often may be required to measure the presence or severity of CIPN in patients with cancer so that steps can be taken to prevent' minimize' or reverse this distressing side effect and avoid treatment interruptions or delays.
The chemotherapeutic agents most often associated with CIPN are platinum compounds, taxanes, vinca alkaloids, thalidomide, and bortezomib.
The FDA admitted in its December 2011 meeting that painful symptoms caused by CIPN are a significant unmet medical need and called on EpiCept to apply for Fast Track designation.
EpiCept had announced in December 2011 that at a meeting with the US Food and Drug Administration (FDA) it was given permission to commence Phase III clinical development of AmiKet for the treatment of CIPN, and that a Special Protocol Assessment (SPA) would be available upon formal submission and agreement as to the Phase III trial protocol.
The FDA said that a CIPN treatment protocol submitted by EpiCept will be reviewed for a Special Protocol Assessment (SPA).
Food and Drug Administration (FDA) for AmiKet[TM] for the treatment of CIPN.
In January 2012, EpiCept engaged SunTrust Robinson Humphrey to assist the Company in exploring strategic alternatives to maximize the commercial opportunity of AmiKet[TM] for the treatment of CIPN following taxane-based therapy.